These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 31937620)

  • 21. Therapeutic targeting of tumor-associated macrophages in pancreatic neuroendocrine tumors.
    Krug S; Abbassi R; Griesmann H; Sipos B; Wiese D; Rexin P; Blank A; Perren A; Haybaeck J; Hüttelmaier S; Rinke A; Gress TM; Michl P
    Int J Cancer; 2018 Oct; 143(7):1806-1816. PubMed ID: 29696624
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in the management of unresectable or metastatic pancreatic neuroendocrine tumors: chemotherapy, targeted therapy, hormonal treatment, and future directions.
    Bilici A
    Asian Pac J Cancer Prev; 2015; 16(6):2151-9. PubMed ID: 25824731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Animal models and cell lines of pancreatic neuroendocrine tumors.
    Babu V; Paul N; Yu R
    Pancreas; 2013 Aug; 42(6):912-23. PubMed ID: 23851429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SQSTM1/p62 is a prognostic molecular marker and potential therapeutic target for pancreatic neuroendocrine tumours.
    Song YL; Weng JH; Zhao DC; Zhang JL; Chen YJ; Xu BH
    Endocrine; 2024 Jul; 85(1):407-416. PubMed ID: 38386167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent Updates in the Management of Advanced Pancreatic Neuroendocrine Tumors.
    Cho CM
    Korean J Gastroenterol; 2019 Mar; 73(3):124-131. PubMed ID: 31013555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis.
    Chiu CW; Nozawa H; Hanahan D
    J Clin Oncol; 2010 Oct; 28(29):4425-33. PubMed ID: 20823411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors.
    Chamberlain CE; German MS; Yang K; Wang J; VanBrocklin H; Regan M; Shokat KM; Ducker GS; Kim GE; Hann B; Donner DB; Warren RS; Venook AP; Bergsland EK; Lee D; Wang Y; Nakakura EK
    Mol Cancer Ther; 2018 Dec; 17(12):2702-2709. PubMed ID: 30254185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metastatic pancreatic neuroendocrine tumors feature elevated T cell infiltration.
    Greenberg J; Limberg J; Verma A; Kim D; Chen X; Lee YJ; Moore MD; Ullmann TM; Thiesmeyer JW; Loewenstein Z; Chen KJ; Egan CE; Stefanova D; Bareja R; Zarnegar R; Finnerty BM; Scognamiglio T; Du YN; Elemento O; Fahey TJ; Min IM
    JCI Insight; 2022 Dec; 7(23):. PubMed ID: 36301668
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel Dual-Action Targeted Nanomedicine in Mice With Metastatic Thyroid Cancer and Pancreatic Neuroendocrine Tumors.
    Nilubol N; Yuan Z; Paciotti GF; Tamarkin L; Sanchez C; Gaskins K; Freedman EM; Cao S; Zhao J; Kingston DGI; Libutti SK; Kebebew E
    J Natl Cancer Inst; 2018 Sep; 110(9):1019-1029. PubMed ID: 29481652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
    Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T
    JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences between Well-Differentiated Neuroendocrine Tumors and Ductal Adenocarcinomas of the Pancreas Assessed by Multi-Omics Profiling.
    Starzyńska T; Karczmarski J; Paziewska A; Kulecka M; Kuśnierz K; Żeber-Lubecka N; Ambrożkiewicz F; Mikula M; Kos-Kudła B; Ostrowski J
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32586046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy.
    Chan JA; Kulke MH
    Surg Oncol Clin N Am; 2016 Apr; 25(2):423-37. PubMed ID: 27013373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression and Molecular Regulation of the Cox2 Gene in Gastroenteropancreatic Neuroendocrine Tumors and Antiproliferation of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).
    Gao F; Zafar MI; Jüttner S; Höcker M; Wiedenmann B
    Med Sci Monit; 2018 Nov; 24():8125-8140. PubMed ID: 30420588
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters.
    Faggiano A; Modica R; Lo Calzo F; Camera L; Napolitano V; Altieri B; de Cicco F; Bottiglieri F; Sesti F; Badalamenti G; Isidori AM; Colao A
    J Clin Endocrinol Metab; 2020 Jan; 105(1):. PubMed ID: 31586182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression profiling of small intestinal neuroendocrine tumors identifies subgroups with clinical relevance, prognostic markers and therapeutic targets.
    Andersson E; Arvidsson Y; Swärd C; Hofving T; Wängberg B; Kristiansson E; Nilsson O
    Mod Pathol; 2016 Jun; 29(6):616-29. PubMed ID: 26965582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mammalian target of rapamycin signaling activation patterns in pancreatic neuroendocrine tumors.
    Komori Y; Yada K; Ohta M; Uchida H; Iwashita Y; Fukuzawa K; Kashima K; Yokoyama S; Inomata M; Kitano S
    J Hepatobiliary Pancreat Sci; 2014 Apr; 21(4):288-95. PubMed ID: 24002888
    [TBL] [Abstract][Full Text] [Related]  

  • 37. mTOR Kinase Inhibition Effectively Decreases Progression of a Subset of Neuroendocrine Tumors that Progress on Rapalog Therapy and Delays Cardiac Impairment.
    Orr-Asman MA; Chu Z; Jiang M; Worley M; LaSance K; Koch SE; Carreira VS; Dahche HM; Plas DR; Komurov K; Qi X; Mercer CA; Anthony LB; Rubinstein J; Thomas HE
    Mol Cancer Ther; 2017 Nov; 16(11):2432-2441. PubMed ID: 28864682
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis.
    Duerr EM; Mizukami Y; Ng A; Xavier RJ; Kikuchi H; Deshpande V; Warshaw AL; Glickman J; Kulke MH; Chung DC
    Endocr Relat Cancer; 2008 Mar; 15(1):243-56. PubMed ID: 18310291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single-cell RNA sequencing reveals spatiotemporal heterogeneity and malignant progression in pancreatic neuroendocrine tumor.
    Zhou Y; Liu S; Liu C; Yang J; Lin Q; Zheng S; Chen C; Zhou Q; Chen R
    Int J Biol Sci; 2021; 17(14):3760-3775. PubMed ID: 34671197
    [No Abstract]   [Full Text] [Related]  

  • 40. Animal models of spontaneous pancreatic neuroendocrine tumors.
    Yu R
    Mol Cell Endocrinol; 2016 Feb; 421():60-7. PubMed ID: 26261055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.